2022.04.04 Press release

--To the press -

FRONTEO's dissertation search AI system "Amanogawa" introduced at Mie University Graduate School of Medicine

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO)Paper search AI system "Amanogawa"Was introduced at the Graduate School of Medicine, Mie University (Location: Tsu City, Mie Prefecture).

 

 Amanogawa is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)".When a researcher inputs a word, sentence, hypothesis, etc. that he / she wants to look up, AI instantly detects related papers from the data of more than 3000 million papers published in PubMed *. AI's vector calculation technology quantifies the relationships and similarities between words and sentences that are used as search conditions, and searches based on the similarity of their meanings and concepts, not just matching as a character string.Therefore, from a huge amount of dissertation information, information that does not hit by keyword search and information that is consistent in notation but has low relevance in content can be identified, and important information can be efficiently obtained from the searcher's knowledge and perspective. It is possible to discover without bias by.This search accuracy and usability, as well as the use of searches that differ from Amanogawa's conventional concept, have been highly evaluated for their ability to increase the probability of discovering new relationships between genes, chemical substances, and diseases. rice field.

 

 On Amanogawa's dashboard screen, the search results are plotted in a map according to the similarity of the paper content, and you can get an overall picture of the number of papers by theme and the relationships between papers at a glance.In addition, various functions such as relevance list display of search results, word cloud, and chronological display greatly improve the efficiency of article search and analysis, which used to take a lot of time for human work.

 

 FRONTEO will continue to work on research and development so that it can contribute to the development of medicine and pharmacy through the provision of AI systems such as Amanogawa.

 

* PubMed: A database of biomedical papers created by the National Center for Biological Sciences in the National Library of Medicine.

 


■ About Concept Encoder
 URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT", "Concept Encoder", and "Looca Cross" specializing in natural language processing to extract meaningful and important information from a huge amount of text data, and is a company. It is a data analysis company that supports the business of. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been developed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc.

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x